GleamWall
中文EN

HSTC HST Global, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 797564 · Fiscal year ends 12/31

Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY30.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-29.7%
ROA-15.8%
ROIC (approx.)-23.1%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets3.3%
Debt / equity0.00x
Current ratio0.25x
Interest coverage-28.94x

Cash quality & payout

Operating cash flow / net income0.38x
Accruals ratio-9.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2024Q32024-09-302024Q22024-06-302024Q12024-03-312023Q4*2023-12-312023Q32023-09-302023Q22023-06-302023Q12023-03-312022Q4*2022-12-31
Income statement
Revenue$0$0$0$0$0$0$0$0
SG&A expense$13,400$16,556$2,688$5,474$4,368$2,990$8,075$4,588
Operating income-$13,400-$16,556-$32,688-$35,474-$34,368-$32,990-$38,075-$34,588
Interest expense$392$84$1,489$1,425$1,362$1,305$1,211$1,123
Pretax income-$13,792-$16,640-$34,177—-$35,730-$34,295-$39,286—
Income tax$0$0$0$0$0$0$0$0
Net income-$13,792-$16,640-$34,177-$36,899-$35,730-$34,295-$39,286-$35,711
EPS (basic)0.000.00-0.01—-0.01-0.01-0.01—
EPS (diluted)——————-0.01—
Weighted avg. shares (diluted)——————5.25M—
Balance sheet
Cash & equivalents$10,406$5,155$838$1,526$2,000$2,320$115$190
Current assets$10,406$5,155$838$1,526$2,000$2,320$115$190
Intangibles$1.27M——$0————
Total assets$1.28M$5,155$838$1,526$2,000$2,320$115$190
Current liabilities$42,076$23,034$627,082$593,593$557,168$521,758$485,258$446,047
Total liabilities$42,076$23,034$627,082$593,593$557,168$521,758$485,258$446,047
Shareholders' equity$1.24M-$17,879-$626,244-$592,067-$555,168-$519,438-$485,143-$445,857
Shares outstanding———5.25M———5.25M
Cash flow statement
Operating cash flow-$18,549$18,517-$32,688-$5,473-$4,369-$2,989-$38,075-$4,588
Investing cash flow—$0$0$0$0$0$0$0
Financing cash flow$23,800-$14,200$32,000$4,999$4,049$5,194$38,000$4,500

Free plan shows the latest 8 periods; Pro shows all 56 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.